Shruti Patel, MD | GI Oncology on Instagram: "Late post from @ascocancer #GI26 but huge news in HER2-positive stomach and esophageal cancer!! A new HER2-targeted therapy (zanidatamab) just showed better results than trastuzumab AKA the drug we’ve relied on for more than 10 years. Both combinations (with chemo, and with chemo + immunotherapy) beat chemo + trastuzumab in a major Phase 3 trial. No numbers yet, but the signal is clear: this could become the new first-line treatment and finally move